. Author manuscript; available in PMC: 2012 Jan 18.

Published in final edited form as: Arch Neurol. 2011 Sep 12;69(1):29–38. doi: 10.1001/archneurol.2011.233

Table 4.

Data on Adverse Events and Percentage of Intent-to-Treat Sample for All Adverse Events Occurring for at Least 5% of the Participants in Any Treatment Group

	Treatment Group

	Placebo		20 IU of Insulin		40 IU of Insulin

Adverse Event	Events, No.	Sample, %	Events, No.	Sample, %	Events, No.	Sample, %
Light-headedness and/or dizziness	3	10.0	3	8.3	5	13.2
Headache not related to lumbar puncture	1	3.3	4	8.3	2	5.3
Nose bleed	0	0.0	6	8.3	3	2.6
Rhinitis	1	3.3	8	16.7	4	7.9
Upper respiratory tract infection	2	6.7	2	5.6	1	2.6
Fall	2	6.7	1	2.8	1	2.6
Rash	2	6.7	1	2.8	2	2.6
Other	16	46.7	30	58.3	33	60.5
Total	27	56.7	55^a	72.2	51^b	68.4

P < .05 for comparison of 20-IU dose insulin group vs placebo group.

P < .10 for comparison of 40-IU dose insulin group vs placebo group.